Welcome to our dedicated page for Protalix Biother news (Ticker: PLX), a resource for investors and traders seeking the latest updates and insights on Protalix Biother stock.
Protalix BioTherapeutics (NYSE: PLX) is a biopharmaceutical innovator leveraging its proprietary ProCellEx® plant cell-based technology to develop enzyme replacement therapies for rare diseases. This page provides investors and industry stakeholders with timely updates on clinical developments, regulatory milestones, and strategic partnerships.
Access comprehensive coverage of PLX's advancements in treating Gaucher disease, Fabry disease, and other rare conditions. Track updates across three key areas: clinical trial progress for pipeline candidates, commercial partnerships with global pharmaceutical leaders, and manufacturing innovations through the ProCellEx® platform.
Our curated news collection enables efficient monitoring of FDA submissions, earnings reports, and licensing agreements. Stay informed about the company's unique approach to cost-effective bioproduction and its expanding role in addressing unmet medical needs through plant-based protein expression systems.
Bookmark this page for direct access to verified press releases and objective analysis of Protalix's position within the competitive rare disease therapeutics market. Regular updates ensure you maintain current awareness of developments impacting both clinical outcomes and investment considerations.
Protalix BioTherapeutics (NYSE: PLX) reported third-quarter 2025 results and a business update on November 13, 2025. YTD revenue was $43.6 million, up 24% year-over-year; Q3 revenue was $17.9 million, down 1% year-over-year. Q3 net income was ~$2.4 million ($0.03/share); YTD net loss was ~$1.1 million ($0.01/share).
R&D spending rose substantially as the company prepares a phase 2 trial of PRX-115; the company submitted an IND in October 2025 that became effective after the FDA 30-day review. A CHMP negative opinion on an Elfabrio dosing variation led to a re-examination request by Chiesi; the approved 1 mg/kg E2W Elfabrio regimen remains unchanged. Cash and equivalents were $29.4 million, stated sufficient for at least 12 months from the quarterly report date.
Protalix BioTherapeutics (NYSE American: PLX) will release its financial results for the quarter ended September 30, 2025 and provide a business update on November 13, 2025.
Management will host a conference call at 8:00 a.m. Eastern Standard Time with toll-free and international dial-ins and a live webcast. Participants are asked to join 15 minutes early to register and install any required audio software. A replay will be available for two weeks on the company's Investors Events Calendar.
Protalix BioTherapeutics (NYSE American:PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using its ProCellEx® plant cell-based protein expression system, has announced its participation in the upcoming Q3 Investor Summit Virtual.
The company's former Senior Vice President and CFO, Eyal Rubin, will deliver a presentation on September 16, 2025, at 10:30 AM EDT. The presentation will focus on the company's growth strategies and market opportunities, and will be accessible via webcast.
Protalix BioTherapeutics (NYSE American:PLX), a biopharmaceutical company specializing in plant cell-based protein expression systems, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
CEO Dror Bashan will deliver a presentation on Monday, September 8, 2025, at 3:30 PM EDT in the Holmes II Room at the Lotte New York Palace Hotel. The management team will also engage in one-on-one meetings with registered investors throughout the conference.
Protalix BioTherapeutics (NYSE American: PLX) reported strong Q2 2025 financial results, with revenues from goods increasing 16% to $15.4 million compared to Q2 2024. The company achieved net income of $164,000 versus a net loss of $2.2 million in the same period last year. The growth was primarily driven by increased sales of Elfabrio® to Chiesi in the $2.3 billion global Fabry disease market.
Key developments include the appointment of Gilad Mamlok as new CFO effective August 24, 2025, replacing Eyal Rubin, and the company's addition to the Russell 3000® and Russell 2000® Indexes. Protalix plans to initiate a Phase 2 trial for PRX-115, their gout treatment candidate, in Q4 2025. The company ended the quarter with $33.4 million in cash and cash equivalents.
Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in ProCellEx® plant cell-based protein expression system, will release its Q2 2025 financial results on August 14, 2025. The company will host a conference call and webcast at 8:30 a.m. EDT to discuss financial results and provide corporate and regulatory updates.
The conference call will be accessible via multiple channels, including toll-free numbers for US and Israeli participants, and will feature a convenient Call me™ feature. A webcast replay will be available for two weeks following the presentation on the company's investor relations website.
Protalix BioTherapeutics (NYSE American: PLX) has appointed Gilad Mamlok as its new Senior Vice President and Chief Financial Officer, effective August 24, 2025. Mamlok brings three decades of experience in healthcare and technology companies, with expertise in capital markets, M&A, and business development.
Mamlok will succeed Eyal Rubin, who will remain available to the company until October 2025 to ensure a smooth transition. Mamlok's recent experience includes CFO positions at TytoCare Ltd. and Sol-Gel Technologies Ltd., where he led significant capital markets transactions and licensing deals. He previously worked at Given Imaging, which was acquired by Covidien in 2014.
Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in plant cell-based protein expression systems, has announced its addition to the Russell 3000® and Russell 2000® Indexes effective June 27, 2025. This inclusion is part of the 2025 Russell indexes annual reconstitution.
The Russell indexes, which benchmark approximately $10.6 trillion in assets, are widely utilized by investment managers and institutional investors. Membership in these indexes is determined by market capitalization rankings and style attributes, with the Russell 3000® Index capturing the 4,000 largest US stocks as of April 30.
Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based expression system, will participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference. The event will take place on Tuesday, May 20, 2025, at the Nasdaq headquarters in New York City.
The company's Sr. Vice President and CFO, Eyal Rubin, will deliver a presentation and be available for one-on-one meetings with investors. The presentation will be webcast live at 4:30 pm EDT and can be accessed through the company's investor relations website or via the provided webcast link.
FAQ
What is the current stock price of Protalix Biother (PLX)?
What is the market cap of Protalix Biother (PLX)?
